COVID-19 vaccine response under scrutiny in autoimmune patients
NCT ID NCT04870411
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study looked at how well the COVID-19 vaccine triggers an immune response in people with autoimmune or inflammatory diseases who take immunosuppressants or biologics. Researchers took blood samples before vaccination and at several points after to measure antibodies and T-cells. The study was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- COVID-19 vaccine (immune response measured via blood samples)
- What this could lead to
- If successful, this could help doctors understand how well COVID-19 vaccines work in people with autoimmune diseases taking immune-suppressing drugs.
- What could go wrong
- The study was terminated early with only 78 participants, so results may be limited and not apply to all patients. Immune response may still be weak in some groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Internal medicine Service - Cochin Hospital
Paris, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.